Charles Edwin Collins IV
Known title: CHIEF EXECUTIVE OFFICER, GEMMACIK: 0001791800
Associated companies
Transaction History
| AGX | ▲ Buy | Option Exercise | 5,000 | $184K | 4/21/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 5,235 | $177K | 4/21/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 500 | $31K | 4/21/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 333 | $50K | 4/21/2026 | View on chart |
| AGX | ▼ Sell | Open Market | 11,068 | $6.9M | 4/21/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 2,500 | $99K | 4/20/2026 | View on chart |
| AGX | ▼ Sell | Open Market | 2,500 | $1.5M | 4/20/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 2,813 | $0 | 4/17/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 1,125 | $0 | 4/17/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 2,531 | $0 | 4/17/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 937 | $0 | 4/17/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 548 | $0 | 4/16/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 360 | $0 | 4/16/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 270 | $0 | 4/16/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 730 | $0 | 4/16/2026 | View on chart |
| AGX | ▲ Buy | Option Exercise | 5,235 | $221K | 10/15/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 4,765 | $161K | 10/15/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 10,000 | $3.1M | 10/15/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 5,235 | $226K | 10/13/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 4,765 | $202K | 10/13/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 10,000 | $2.9M | 10/13/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 5,000 | $216K | 10/1/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 5,000 | $1.4M | 10/1/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 5,000 | $216K | 9/24/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 5,000 | $1.3M | 9/24/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 7,500 | $323K | 9/18/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 7,500 | $1.9M | 9/18/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 5,000 | $1.2M | 7/31/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 1,500 | $362K | 7/29/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 765 | $35K | 6/9/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 500 | $31K | 6/9/2025 | View on chart |
| AGX | ▼ Sell | Open Market | 1,265 | $305K | 6/9/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 1,914 | $0 | 4/18/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 2,583 | $0 | 4/18/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 1,147 | $0 | 4/18/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 931 | $0 | 4/17/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 838 | $0 | 4/17/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 725 | $0 | 4/16/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 544 | $0 | 4/16/2025 | View on chart |
| AGX | ▲ Buy | Option Exercise | 1,886 | $0 | 4/18/2024 | View on chart |
| AGX | ▲ Buy | Option Exercise | 848 | $0 | 4/18/2024 | View on chart |
| AGX | ▲ Buy | Option Exercise | 918 | $0 | 4/17/2024 | View on chart |
| AGX | ▲ Buy | Option Exercise | 826 | $0 | 4/17/2024 | View on chart |
| AGX | ▲ Buy | Option Exercise | 964 | $0 | 4/16/2024 | View on chart |
| AGX | ▲ Buy | Option Exercise | 3,424 | $0 | 4/18/2023 | View on chart |
| AGX | ▲ Buy | Option Exercise | 1,753 | $0 | 4/16/2023 | View on chart |
| AGX | ▲ Buy | Option Exercise | 1,705 | $0 | 4/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
JP Morgan Lowers Argan Price Target to $785
JP Morgan maintained its Overweight rating on Argan but lowered its price target to $785. This action follows the company's Q2 earnings beat and the acquisition of ValCor. Despite recent stock weakness, analysts continue to highlight the firm's positioning in the electrification sector.
JP Morgan Lowers Argan Price Target to $785. JP Morgan maintained its Overweight rating on Argan but lowered its price target to $785. This action follows the company's Q2 earnings beat and the acquisition of ValCor. Despite recent stock weakness, analysts continue to highlight the firm's positioning in the electrification sector.